abstract |
The present disclosure provides a composition for use in the treatment of dystrophic epidermal blisters, comprising cells of a dystrophic epidermal blisters patient genetically modified to produce type VII collagen, wherein the cells are mesenchymal stem cells. it's about The present disclosure also relates to a composition for use in the treatment of dystrophic epidermal blisters, comprising type VII collagen-producing cells, and administered intravesicularly. |